Thomas J. Hudson

Last updated
Thomas J. Hudson
Born(1961-06-12)June 12, 1961
Arvida, Quebec, Canada
Education Université de Montréal (MD 1985)
Known forContribution to developing a haplotype map of the human genome.
Scientific career
FieldsHuman genomics
Institutions McGill University Health Centre, Massachusetts Institute of Technology, Whitehead Institute/MIT Center for Genome Research, Ontario Institute for Cancer Research
Academic advisors Emil Skamene, David Housman

Thomas James Hudson, O.C., (born June 12, 1961) is a Canadian genome scientist noted for his leading role in the generation of physical maps of the human and mouse genomes and also his role in the International HapMap Project whose goal is to develop a haplotype map of the human genome.

Contents

As director of the McGill University and Genome Quebec Innovation Centre, which he established, Hudson and his team have made a number of discoveries in human genetics. These include genes mutated in rare diseases and genes involved in complex diseases such as asthma, type II diabetes and inflammatory bowel disease.

In July 2006, he was appointed president and scientific director of the Ontario Institute for Cancer Research. He is also editor-in-chief of the journal Human Genetics . [1]

Thomas Hudson is married and has five children. [2]

Beginnings and early career

Hudson was born in 1961 in Arvida, Quebec, where his father was a chemist for Alcan. [3] He has six sisters including a twin sister. [2] He earned his M.D. degree in 1985 from the Université de Montréal. Then, he did residencies in internal medicine and Clinical Immunology and Allergy, the latter at McGill University Health Centre. In 1990, after a year of postdoctoral experience under the supervision of Emil Skamene and Danuta Radzioch, he went to the Massachusetts Institute of Technology for a fellowship with David Housman.

There he became involved with Eric Lander's projects and eventually led the effort to build a physical map of the human genome, which was an important step towards the generation of the complete sequence of the human genome. He supervised a large team of engineers, biologists, computer scientists to build high throughput PCR systems. The robot built by his team, called the "Genomatron", performed up to 300,000 PCR reactions per day. He was also part of an international effort to build a transcript map of the human genome. By 1996, his team had mapped more than 10,000 genes. In 1995, he became the assistant director of the Whitehead Institute/MIT Center for Genome Research a position which he held until 2001.

Montreal Genome Centre

In 1996, Hudson was recruited back to Montreal at the McGill University Health Centre where he created the Montreal Genome Centre. In 2003, Hudson expanded his team and moved into a new building on the McGill University campus called the McGill University and Genome Quebec Innovation Centre. The Centre possesses five different technology platforms (genotyping, sequencing, expression profiling, mass spectrometry and Information Technology) and also provides services to the Canadian and International community. By 2006, more than four hundred academic laboratories as well as a dozen of biotechnology companies have used the services of this new facility.

Until 2006, Hudson was also an associate professor in the departments of Human Genetics and Medicine at McGill University and associate physician at the McGill University Health Centre (Division of Immunology and Allergy). The main focus of his research is on the genetic dissection of complex diseases. His most important discoveries include the identification of genes involved in the development of Type II diabetes, susceptibility to leprosy, multiple sclerosis, asthma and inflammatory bowel disease. His team findings also include rare disease mutations such as the genes for spastic ataxia of Charlevoix-Saguenay (ARSACS) [4] and Leigh syndrome French-Canadian Type (also known as lactic acidosis), [5] that affect many families from the Saguenay region, of which he is a native.

One of his publications on inflammatory bowel disease in 2001 was the catalyst that led to the launch of the International HapMap project. [6] More than 200 researchers from six different countries, including Hudson and his team, worked on the project. The HapMap, which was completed in October 2005, is a catalog of genetic variations - called single nucleotide polymorphisms (SNPs) - and will help in discovering how these variations correlate with risk of developing complex diseases.

Leadership in Canada

Hudson has been a key player in many national organizations. He was Associate Director of the Canadian Genetics Disease Network from 2001 to 2005, and he has helped launch Genome Canada and Genome Quebec, of which he was the first scientific director in 2002. In addition, he has been a member of the Scientific Advisory Board for many public organizations or private companies.

New horizons

In July 2006, Hudson announced that he was leaving Montreal to lead the newly created Ontario Institute for Cancer Research in Toronto, Ontario which will focus on the genomics of cancer. [7] Hudson remained acting scientific director of the McGill University and Genome Quebec Innovation Centre, until his successor Mark Lathrop succeeded him in 2011. [8] Currently, Hudson is serving as Senior Vice President, R&D, and Chief Scientific Officer at AbbVie. [9]

Awards

Hudson's accomplishments have been recognized by numerous awards and honors:

Related Research Articles

<span class="mw-page-title-main">Michael Smith (chemist)</span> British-born Canadian biochemist, businessman and Nobel Prize laureate (1932–2000)

Michael Smith was a British-born Canadian biochemist and businessman. He shared the 1993 Nobel Prize in Chemistry with Kary Mullis for his work in developing site-directed mutagenesis. Following a PhD in 1956 from the University of Manchester, he undertook postdoctoral research with Har Gobind Khorana at the British Columbia Research Council in Vancouver, British Columbia, Canada. Subsequently, Smith worked at the Fisheries Research Board of Canada Laboratory in Vancouver before being appointed a professor of biochemistry in the UBC Faculty of Medicine in 1966. Smith's career included roles as the founding director of the UBC Biotechnology Laboratory and the founding scientific leader of the Protein Engineering Network of Centres of Excellence (PENCE). In 1996 he was named Peter Wall Distinguished Professor of Biotechnology. Subsequently, he became the founding director of the Genome Sequencing Centre at the BC Cancer Research Centre.

<span class="mw-page-title-main">Marco Marra</span> Canadian geneticist

Marco A. Marra is a Distinguished Scientist and Director of Canada's Michael Smith Genome Sciences Centre at the BC Cancer Research Centre and Professor of Medical Genetics at the University of British Columbia (UBC). He also serves as UBC Canada Research Chair in Genome Science for the Canadian Institutes of Health Research and is an inductee in the Canadian Medical Hall of Fame. Marra has been instrumental in bringing genome science to Canada by demonstrating the pivotal role that genomics can play in human health and disease research.

The International HapMap Project was an organization that aimed to develop a haplotype map (HapMap) of the human genome, to describe the common patterns of human genetic variation. HapMap is used to find genetic variants affecting health, disease and responses to drugs and environmental factors. The information produced by the project is made freely available for research.

Charles Robert Scriver was a Canadian pediatrician and biochemical geneticist. His work focused on inborn errors of metabolism and led in establishing a Canada-wide newborn metabolic screening program.

<span class="mw-page-title-main">Wellcome Sanger Institute</span> British genomics research institute

The Wellcome Sanger Institute, previously known as The Sanger Centre and Wellcome Trust Sanger Institute, is a non-profit British genomics and genetics research institute, primarily funded by the Wellcome Trust.

<span class="mw-page-title-main">Bartha Knoppers</span> Canadian lawyer and scientist

Bartha Maria Knoppers, OC OQ is a Canadian law Professor and an expert on the ethical aspects of genetics, genomics and biotechnology.

<span class="mw-page-title-main">Interleukin-23 receptor</span> Protein-coding gene in the species Homo sapiens

The interleukin-23 receptor is a type I cytokine receptor. It is encoded in human by the IL23R gene. In complex with the interleukin-12 receptor β1 subunit (IL-12Rβ1), it is activated by the cytokine interleukin 23 (IL-23). The IL23R mRNA is 2.8 kilobases in length and includes 12 exons. The translated protein contains 629 amino acids; it is a type I penetrating protein and includes a signal peptide, an N-terminal fibronectin III-like domain and an intracellular part that contains three potential tyrosine phosphorylation domains. There are 24 IL23R splice variants in mitogen-activated lymphocytes. IL23R includes some single-nucleotide polymorphisms in the region encoding the domain that binds IL-23, which may lead to differences between people in Th17 activation. There is also a variant of IL-23R that consists of just the extracellular part and is known as soluble IL-23R. This form can compete with the membrane-bound form to bind IL-23, modulating the Th17 immune response and regulation of inflammation and immune function.

Expenditures by Canadian universities on scientific research and development accounted for about 40% of all spending on scientific research and development in Canada in 2006.

This article outlines the history of natural scientific research in Canada, including physics, astronomy, space science, geology, oceanography, chemistry, biology, and medical research. Neither the social sciences nor the formal sciences are treated here.

Rima Rozen is a Canadian geneticist who is a professor at McGill University. Her current research focuses on genetic and nutritional deficiencies in folate metabolism and their impact on complex traits.

<span class="mw-page-title-main">Judes Poirier</span>

Judes Poirier is Canadian-born professor of Medicine and Psychiatry at McGill University and former director of the Centre for Studies in Aging at McGill University. He currently serves as director of the Molecular Neurobiology Unit at the Douglas Institute Research Centre and, co-founder and associate director of the Centre for the Studies on the Prevention of Alzheimer's disease at McGill University.

CARTaGENE is a population-based cohort based on an ongoing and long-term health study of 40,000 men and women in Québec. It is a regional cohort member of the Canadian Partnership for Tomorrow's Health (CanPath). The project's core mandate is to identify the genetic and environmental causes of common chronic diseases affecting the Québec population, and to develop personalized medicine and public policy initiatives targeting high-risk groups for the public.

Philip Awadalla is a professor of medical and population genetics at the Ontario Institute for Cancer Research, and the Department of Molecular Genetics, Faculty of Medicine, University of Toronto. He is the National Scientific Director of the Canadian Partnership for Tomorrow's Health (CanPath), formerly the Canadian Partnership for Tomorrow Project (CPTP), and executive director of the Ontario Health Study. He is also the Executive Scientific Director of the Genome Canada Genome Technology Platform, the Canadian Data Integration Centre. Professor Awadalla was the Executive Scientific Director of the CARTaGENE biobank, a regional cohort member of the CPTP, from 2009 to 2015, and is currently a scientific advisor for this and other scientific and industry platforms. At the OICR, he is Director of Computational Biology.

<span class="mw-page-title-main">Gonçalo Abecasis</span> Portuguese researcher

Gonçalo Rocha Abecasis is a Portuguese American biomedical researcher at the University of Michigan, serves as Vice President & Chief Genomics and Data Science Officer at the Regeneron Genetics Center, and was chair of the Department of Biostatistics in the School of Public Health. He leads a group at the Center for Statistical Genetics in the Department of Biostatistics, where he is also the Felix E. Moore Collegiate Professor of Biostatistics and director of the Michigan Genomic Initiative. His group develops statistical tools to analyze the genetics of human disease.

<span class="mw-page-title-main">Yusuke Nakamura (geneticist)</span> Medical researcher in Japan

Yusuke Nakamura is a Japanese prominent geneticist and cancer researcher best known for developing Genome-Wide Association Study (GWAS). He is one of the world's pioneers in applying genetic variations and whole genome sequencing, leading the research field of personalized medicine.

B K Thelma commonly known as Bittianda Kuttapa Thelma is a professor in the Department of Genetics at the University of Delhi, South Campus, New Delhi, India. She is the Principal investigator and Co-ordinator of the Centre of excellence on Genomes Sciences and Predictive Medicine funded by the Govt. of India. She is also the Co-ordinator of a major project on newborn screening for inborn errors of metabolism in Delhi state which aims to demonstrate the feasibility of mandatory screening of newborns in the country and to generate epidemiological data for the testable IEMs in the genetically distinct Indian population, for the first time.

Mark Joseph Daly is Director of the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki, a Professor of Genetics at Harvard Medical School, Chief of the Analytic and Translational Genetic Unit at Massachusetts General Hospital, and a member of the Broad Institute of MIT and Harvard. In the early days of the Human Genome Project, Daly helped develop the genetic model by which linkage disequilibrium could be used to map the haplotype structure of the human genome. In addition, he developed statistical methods to find associations between genes and disorders such as Crohn's disease, inflammatory bowel disease, autism and schizophrenia.

<span class="mw-page-title-main">Charles Rotimi</span> Nigerian geneticist

Charles Nohuoma Rotimi is the Scientific Director of the National Human Genome Research Institute (NHGRI). He joined the National Institutes of Health (NIH) in 2008 as the inaugural Director of the Trans-NIH Center for Research in Genomics and Global Health and was also the chief of the NHGRI's Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch. He works to ensure that population genetics include genomes from African populations and founded the African Society of Human Genetics in 2003 and was elected its first president. Rotimi was instrumental in the launch of the Human Heredity and Health in Africa (H3Africa) with the NIH and the Wellcome Trust. He was elected to the National Academy of Medicine in 2018.

Sylvie Cloutier is a Canadian scientist. She is a specialist in molecular genetics at Agriculture and Agri-Food Canada's Ottawa Research and Development Centre and an adjunct professor at the University of Ottawa. She has co-led two Genome Canada Large Scale Applied Research projects of $11M each and has been involved in over 110 published research papers and made contributions to many books.

<span class="mw-page-title-main">Andre Franke</span> German geneticist

Andre Franke, born on 16 October 1978, is a geneticist, academic, and university professor. He is a Full W3 Professor of Molecular Medicine at the Christian-Albrechts-University of Kiel, and a managing director at the Institute of Clinical Molecular Biology.

References

  1. ↑ "OICR Press Release". Archived from the original on 2006-08-21. Retrieved 2006-09-16.
  2. 1 2 3 "Burroughs-Wellcome recipient profile". Archived from the original on 2007-09-28. Retrieved 2006-09-15.
  3. ↑ "Genes/Genomes news" . Retrieved 2006-09-16.
  4. ↑ Online Mendelian Inheritance in Man (OMIM): spastic ataxia Charlevoix-Saguenay type - 270550
  5. ↑ Online Mendelian Inheritance in Man (OMIM): Leigh syndrome French Canadian type - 220111
  6. ↑ "Genome Canada Press Release". Archived from the original on 2007-09-27. Retrieved 2006-09-15.
  7. ↑ "Globe and Mail story". The Globe and Mail . Retrieved 2006-11-16.[ dead link ]
  8. ↑ "Trailblazing gene researcher returns to Canada". The Globe and Mail. 14 February 2011. Retrieved 2012-12-21.
  9. ↑ "Partner Spotlight: Thomas Hudson, Abbvie". 8 February 2018.
  10. ↑ "Canada Gazette" . Retrieved 2013-08-31.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.